BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 8639793)

  • 1. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
    Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
    Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4.
    Debinski W; Obiri NI; Pastan I; Puri RK
    J Biol Chem; 1995 Jul; 270(28):16775-80. PubMed ID: 7622490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4.
    Kornmann M; Kleeff J; Debinski W; Korc M
    Anticancer Res; 1999; 19(1A):125-31. PubMed ID: 10226533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin-induced cell death by gene transfer of interleukin 13 receptor alpha chain.
    Kawakami K; Joshi BH; Puri RK
    Hum Gene Ther; 2000 Sep; 11(13):1829-35. PubMed ID: 10986556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin.
    Maini A; Hillman G; Haas GP; Wang CY; Montecillo E; Hamzavi F; Pontes JE; Leland P; Pastan I; Debinski W; Puri RK
    J Urol; 1997 Sep; 158(3 Pt 1):948-53. PubMed ID: 9258124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein.
    Husain SR; Obiri NI; Gill P; Zheng T; Pastan I; Debinski W; Puri RK
    Clin Cancer Res; 1997 Feb; 3(2):151-6. PubMed ID: 9815666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
    Kawakami K; Kawakami M; Joshi BH; Puri RK
    Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin.
    Joshi BH; Kawakami K; Leland P; Puri RK
    Clin Cancer Res; 2002 Jun; 8(6):1948-56. PubMed ID: 12060640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin.
    Puri RK; Debinski W; Obiri N; Kreitman R; Pastan I
    Cell Immunol; 1994 Apr; 154(1):369-79. PubMed ID: 8131209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells.
    Debinski W; Miner R; Leland P; Obiri NI; Puri RK
    J Biol Chem; 1996 Sep; 271(37):22428-33. PubMed ID: 8798406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity.
    Puri RK; Leland P; Obiri NI; Husain SR; Mule J; Pastan I; Kreitman RJ
    Cell Immunol; 1996 Jul; 171(1):80-6. PubMed ID: 8660841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft.
    Husain SR; Puri RK
    Blood; 2000 Jun; 95(11):3506-13. PubMed ID: 10828036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin.
    Debinski W; Obiri NI; Powers SK; Pastan I; Puri RK
    Clin Cancer Res; 1995 Nov; 1(11):1253-8. PubMed ID: 9815919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells.
    Kawakami M; Kawakami K; Puri RK
    Cancer Immunol Immunother; 2002 Feb; 50(12):691-700. PubMed ID: 11862421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
    Han J; Yang L; Puri RK
    J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
    Husain SR; Joshi BH; Puri RK
    Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts.
    Kawakami K; Husain SR; Bright RK; Puri RK
    Cancer Gene Ther; 2001 Nov; 8(11):861-8. PubMed ID: 11773976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
    Husain SR; Puri RK
    J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.
    Kawakami K; Husain SR; Kawakami M; Puri RK
    Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
    Kioi M; Kawakami K; Puri RK
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.